rs12293259 - SMIM38 - MYEOV
Magnitude 2.2 · 1 study on file
Reported associations
-
Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa. - Nature genetics (2024) · Janivara R, Chen WC, Hazra U, Baichoo S, Agalliu I, Kachambwa P, Simonti CN, Brown LM, Tambe SP, Kim MS, Harlemon M, Jalloh M, Muzondiwa D, Naidoo D, Ajayi OO, Snyper NY, Niang L, Diop H, Ndoye M, Mensah JE, Abrahams AOD, Biritwum R, Adjei AA, Adebiyi AO, Shittu O, Ogunbiyi O, Adebayo S, Nwegbu MM, Ajibola HO, Oluwole OP, Jamda MA, Pentz A, Haiman CA, Spies PV, van der Merwe A, Cook MB, Chanock SJ, Berndt SI, Watya S, Lubwama A, Muchengeti M, Doherty S, Smyth N, Lounsbury D, Fortier B, Rohan TE, Jacobson JS, Neugut AI, Hsing AW, Gusev A, Aisuodionoe-Shadrach OI, Joffe M, Adusei B, Gueye SM, Fernandez PW, McBride J, Andrews C, Petersen LN, Lachance J, Rebbeck TR · PubMed 39358599
Men of African descent have the highest prostate cancer incidence and mortality rates, yet the genetic basis of prostate cancer in African men has been understudied. We used genomic data from 3,963 cases and 3,509 controls from Ghana, Nigeria, Senegal, South Africa and Uganda to infer ancestry-specific genetic architectures and fine-map disease associations. Fifteen independent associations at 8q24.21, 6q22.1 and 11q13.3 reached genome-wide significance, including four new associations. Intriguingly, multiple lead associations are private alleles, a pattern arising from recent mutations and the out-of-Africa bottleneck. These African-specific alleles contribute to haplotypes with odds ratios above 2.4. We found that the genetic architecture of prostate cancer differs across Africa, with ef
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
prostate cancer screening timing Moderate
G allele carriers have significantly increased prostate cancer risk (GWAS p=2e-7, n=7472)
Discuss with physician; consider risk stratification and screening decisions based on individual factors